Kyverna Therapeutics said it plans to submit its CAR-T therapy for stiff person syndrome to the FDA by mid-year after presenting study results showing improved mobility and reduced disability. The program, once authorized, would be positioned as the first treatment for stiff person syndrome and the first personalized CAR-T therapy for an autoimmune disease to reach the market. CAR-T in autoimmunity is built around B-cell depletion to reset immune activity, and Kyverna’s update places it among the closest approaches to entering clinical mainstream for this rare neurologic autoimmune condition. The submission timeline will be watched closely by the autoimmune CAR-T segment for both regulatory precedent and manufacturing feasibility at scale.